NAV

Fasoracetam

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Fasoracetam
DrugBank Accession Number
DB16163
Background

Fasoracetam is under investigation in clinical trial NCT03609619 (PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without Mglur Mutations).

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 196.25
Monoisotopic: 196.121177763
Chemical Formula
C10H16N2O2
Synonyms
  • Fasoracetam
External IDs
  • AEVI-001
  • LAM-105
  • NS-105
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
42O8UF5CJB
CAS number
110958-19-5
InChI Key
GOWRRBABHQUJMX-MRVPVSSYSA-N
InChI
InChI=1S/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1
IUPAC Name
(5R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one
SMILES
O=C([C@H]1CCC(=O)N1)N1CCCCC1

References

General References
Not Available
KEGG Compound
C13311
ChemSpider
171980
ChEBI
31592
ChEMBL
CHEMBL2106179
ZINC
ZINC000003779713
Wikipedia
Fasoracetam

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAttention Deficit Hyperactivity Disorder (ADHD)2
1CompletedTreatmentAttention Deficit Hyperactivity Disorder (ADHD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility108.0 mg/mLALOGPS
logP0.27ALOGPS
logP-0.4Chemaxon
logS-0.26ALOGPS
pKa (Strongest Acidic)11.65Chemaxon
pKa (Strongest Basic)-2.2Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area49.41 Å2Chemaxon
Rotatable Bond Count1Chemaxon
Refractivity51.85 m3·mol-1Chemaxon
Polarizability20.69 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03ea-4900000000-4dc44c9bd30cbc8034e5
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-1900000000-bbe0eac8b23379f80079
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0016-9100000000-be47d754d0f8b82d0891
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9500000000-f6095b548bc1683942ce
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0ldi-9700000000-3784d4da52ec3bd6a9ea
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-000x-9300000000-a63bd295ef0ce9d81f19
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-147.9991726
predicted
DarkChem Lite v0.1.0
[M-H]-144.61931
predicted
DeepCCS 1.0 (2019)
[M+H]+148.9404726
predicted
DarkChem Lite v0.1.0
[M+H]+146.9497
predicted
DeepCCS 1.0 (2019)
[M+Na]+152.9459
predicted
DeepCCS 1.0 (2019)

Drug created at December 15, 2020 18:14 / Updated at February 21, 2021 18:55